These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10878820)

  • 1. VHL takes HIF's breath away.
    Krek W
    Nat Cell Biol; 2000 Jul; 2(7):E121-3. PubMed ID: 10878820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
    Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K; Makino Y; Pereira T; Poellinger L
    EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME; Masson N; Mole DR; Jaakkola P; Chang GW; Clifford SC; Maher ER; Pugh CW; Ratcliffe PJ; Maxwell PH
    J Biol Chem; 2000 Aug; 275(33):25733-41. PubMed ID: 10823831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
    Jaakkola P; Mole DR; Tian YM; Wilson MI; Gielbert J; Gaskell SJ; von Kriegsheim A; Hebestreit HF; Mukherji M; Schofield CJ; Maxwell PH; Pugh CW; Ratcliffe PJ
    Science; 2001 Apr; 292(5516):468-72. PubMed ID: 11292861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer. Many vessels, faulty gene.
    Kaelin WG
    Nature; 1999 May; 399(6733):203-4. PubMed ID: 10353237
    [No Abstract]   [Full Text] [Related]  

  • 12. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor protein.
    Ivan M; Kaelin WG
    Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.
    Mole DR; Maxwell PH; Pugh CW; Ratcliffe PJ
    IUBMB Life; 2001 Jul; 52(1-2):43-7. PubMed ID: 11795592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
    Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
    J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW; Ratcliffe PJ
    Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Hippel-Lindau tumor suppressor: not only HIF's executioner.
    Czyzyk-Krzeska MF; Meller J
    Trends Mol Med; 2004 Apr; 10(4):146-9. PubMed ID: 15162797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
    Kamura T; Sato S; Iwai K; Czyzyk-Krzeska M; Conaway RC; Conaway JW
    Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10430-5. PubMed ID: 10973499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation.
    Masson N; Willam C; Maxwell PH; Pugh CW; Ratcliffe PJ
    EMBO J; 2001 Sep; 20(18):5197-206. PubMed ID: 11566883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.